Key Highlights
- Phase 3 data on INCB161734 in KRAS G12D-mutated pancreatic cancer due October 24.
- Separate Phase 3 data on INCB123667 plus bevacizumab in ovarian cancer due October 26.
- Programs are known as DAWN-303 and MAESTRA 3/GOG-3146/ENGOT-OV106, respectively.
- Incyte shares trade near $117.25, with a market value of about $23.42 billion.
Incyte Corporation (NASDAQ: INCY) is scheduled to present two separate Phase 3 oncology readouts at the ESMO 2026 congress, covering candidates in pancreatic cancer and ovarian cancer.
What Happened
The first program, INCB161734, is being studied in previously untreated, KRAS G12D-mutated metastatic pancreatic ductal adenocarcinoma under the DAWN-303 trial, with Phase 3 data scheduled for ESMO on October 24, 2026.
The second program, INCB123667, a CDK2 inhibitor combined with bevacizumab, is being studied versus bevacizumab alone in advanced epithelial ovarian and fallopian tube cancer, under the MAESTRA 3 (GOG-3146; ENGOT-OV106) trial. That Phase 3 study is ongoing, with data scheduled for ESMO on October 26, 2026.
Market Reaction
Incyte, a large-cap biopharmaceutical company valued at approximately $23.42 billion, traded near $117.25 per share, up $0.60, or 0.51%, according to the disclosed pipeline database.
Outlook
Phase 3 data for INCB161734 in pancreatic cancer is scheduled for October 24, 2026, while Phase 3 data for INCB123667 in ovarian cancer is scheduled for October 26, 2026, both at the ESMO congress.
What cancer types are Incyte's two ESMO readouts covering?
One Phase 3 readout covers KRAS G12D-mutated metastatic pancreatic cancer (INCB161734), and the other covers advanced epithelial ovarian and fallopian tube cancer (INCB123667).
When will Incyte present its pancreatic cancer data?
Phase 3 data on INCB161734 in the DAWN-303 trial is scheduled for ESMO on October 24, 2026.
When will Incyte present its ovarian cancer data?
Phase 3 data on INCB123667 in the MAESTRA 3 trial is scheduled for ESMO on October 26, 2026.






Please wait processing your request...